403-32-7

Usage

Uses

Used in Pharmaceutical Industry:
(4-FLUORO-PHENYL)-OXO-ACETALDEHYDE is used as a synthetic intermediate for the development of novel pharmaceutical compounds. Its unique structure allows for the creation of new drugs with potential applications in treating various diseases and medical conditions.
Used in Chemical Research:
In the field of chemical research, (4-FLUORO-PHENYL)-OXO-ACETALDEHYDE serves as a valuable compound for studying the reactivity and properties of fluorinated aromatic systems. Its use in research can lead to a better understanding of the underlying chemical mechanisms and the development of new synthetic methodologies.
Used in Material Science:
(4-FLUORO-PHENYL)-OXO-ACETALDEHYDE is used as a precursor in the synthesis of advanced materials, such as fluorinated polymers and coatings. These materials can exhibit enhanced properties, such as increased chemical stability, improved thermal resistance, and reduced friction, making them suitable for various industrial applications.
Used in Agrochemical Industry:
In the agrochemical industry, (4-FLUORO-PHENYL)-OXO-ACETALDEHYDE is used as a key intermediate in the synthesis of new pesticides and agrochemicals. Its incorporation into these compounds can lead to improved efficacy, selectivity, and reduced environmental impact.
Overall, (4-FLUORO-PHENYL)-OXO-ACETALDEHYDE is a versatile and valuable compound with a wide range of applications across various industries, including pharmaceuticals, chemical research, material science, and agrochemicals. Its unique chemical properties and reactivity make it an essential component in the development of new and innovative products.

InChI:InChI=1/C8H5FO2.H2O/c9-7-3-1-6(2-4-7)8(11)5-10;/h1-5H;1H2

Upstream product

• 403-42-9 1-(4-fluorophenyl)ethanone 
• 462-06-6 fluorobenzene 
• 405-99-2 para-fluorostyrene 
• 403-31-6 4-fluoro-2-hydroxy-acetophenone 

Downstream Products

• 81593-29-5 5-(4-fluorophenyl)-1-phenylhydantoin 
• 81593-37-5 5-(4-Fluoro-phenyl)-1-p-tolyl-imidazolidine-2,4-dione 
• 121041-71-2 2-(4-Fluoro-phenyl)-6-(2-methoxy-phenoxy)-imidazo[1,2-b]pyridazin-3-ol 
• 107128-47-2 5-(4-fluorophenyl)-1,2,4-triazin-3-amine 
• 447-43-8 1-(4-fluorophenyl)-2,2-dihydroxyethan-1-one 
• 157429-18-0 C₉H₈FN₃OS 
• 362610-10-4 2,2-difluoro-2-(4-fluorophenyl)acetaldehyde 
• 935479-78-0 2,2-bis-benzyloxy-1-(4-fluoro-phenyl)-ethanone 

Relevant academic research and scientific papers

SUBSTITUTED ARYL COMPOUND AND PREPARATION METHOD THEREFOR AND USE THEREOF

The present application relates to a substituted aryl compound or a pharmaceutically acceptable salt, a stereoisomer, a polymorph, a solvate, a N-oxide, an isotope-labeled compound, a metabolite or a prodrug thereof, and a preparation method therefor and use thereof, also relates to a pharmaceutical composition containing the compound and a therapeutic use thereof. The compound or a pharmaceutical composition thereof can inhibit the activity of adenosine A2a receptor, and can be used for treating or preventing a disease related to adenosine A2a receptor, especially for treating a tumor.

A novel class for carbonic anhydrases inhibitors and evaluation of their non-zinc binding

In this study, 23 different imidazole derivatives were synthesized, and the inhibitory properties of these derivatives against carbonic anhydrase I and II isoenzymes were investigated for the first time. The inhibition concentrations of the imidazole derivatives were found to be in the range of 2.89–115.5 nM. Docking studies examined the binding properties of the imidazole derivatives, and the structure–activity relationship is discussed. Theoretical calculations showed that the binding mode of the imidazole ring was non-zinc binding.

Ynonylation of Acyl Radicals by Electroinduced Homolysis of 4-Acyl-1,4-dihydropyridines

Herein we report the conversion of 4-Acyl-1,4-dihydropyridines (DHPs) into ynones under electrochemical conditions. The reaction proceeds via the homolysis of acyl-DHP under electron activation. The resulting acyl radicals react with hypervalent iodine(III) reagents to form the target ynones or ynamides in acceptable yields. This mild reaction condition allows wider functionality tolerance that includes halides, carboxylates, or alkenes. The synthetic utility of this methodology is further demonstrated by the late-stage modification of complex molecules.

Structural Basis for EGFR Mutant Inhibition by Trisubstituted Imidazole Inhibitors

Acquired drug resistance in epidermal growth factor receptor (EGFR) mutant non-small-cell lung cancer is a persistent challenge in cancer therapy. Previous studies of trisubstituted imidazole inhibitors led to the serendipitous discovery of inhibitors that target the drug resistant EGFR(L858R/T790M/C797S) mutant with nanomolar potencies in a reversible binding mechanism. To dissect the molecular basis for their activity, we determined the binding modes of several trisubstituted imidazole inhibitors in complex with the EGFR kinase domain with X-ray crystallography. These structures reveal that the imidazole core acts as an H-bond acceptor for the catalytic lysine (K745) in the "αC-helix out" inactive state. Selective N-methylation of the H-bond accepting nitrogen ablates inhibitor potency, confirming the role of the K745 H-bond in potent, noncovalent inhibition of the C797S variant. Insights from these studies offer new strategies for developing next generation inhibitors targeting EGFR in non-small-cell lung cancer.

1-phenyl-2-phenylaminoethyl ketone derivative and medical application

The invention belongs to the field of pharmaceutical chemicals, and relates to a micromolecular inhibitor of polymyxin drug-resistant protein MCR-1 and application thereof. The invention relates to acompound shown as a formula I, a pharmaceutically accept

Pyrimidine-containing tri-substituted imidazole compound and application thereof

The invention relates to a pyrimidine-containing tri-substituted imidazole compound and application thereof. The compound has a structure shown as a formula (I). The compound can be used for effectively inhibiting EGFR (epidermal growth factor receptor) C797S mutation including EGFR ex19del/T790M/C797S and L858R/T790M/C797S; meanwhile, the compounds also have high inhibitory activity on single-point mutation L858R, ex19del and double-point mutation such as L858R/T790M, ex19del/T790M and the like, and moreover, the compounds have a weak inhibitory effect on wild EGFR (epidermal growth factor receptor), namely, the compounds have very good selectivity. The compound has potential to become a drug for treating malignant tumors carrying EGFR C797S mutation, especially non-small cell lung cancer(NSCLC), and has great application value.

Design, synthesis and biological evaluation of 1-Phenyl-2-(phenylamino) Ethanone Derivatives as Novel MCR-1 Inhibitors

Polymyxins are considered to be the last-line antibiotics that are used to treat infections caused by multidrug-resistant (MDR) gram-negative bacteria; however, the plasmid-mediated transferable colistin resistance gene (mcr-1) has rendered polymyxins ine

Mono- or di-substituted imidazole derivatives for inhibition of acetylcholine and butyrylcholine esterases

Mono- or di-substituted imidazole derivatives were synthesized using a one-pot, two-step strategy. All imidazole derivatives were tested for AChE and BChE inhibition and showed nanomolar activity similar to that of the test compound donepezil and higher than that of tacrine. Structure activity relationship studies, docking studies to on X-ray crystal structure of AChE with PDB code 1B41, and adsorption, distribution, metabolism, and excretion (ADME) predictions were performed. The synthesized core skeleton was bound to important regions of the active site of AChE such as the peripheral anionic site (PAS), oxyanion hole (OH), and anionic subsite (AS). Selectivity of the reported test compounds was calculated and enzyme kinetic studies revealed that they behave as competitive inhibitors, while two of the test compounds showed noncompetitive inhibitory behavior. ADME predictions revealed that the synthesized molecules might pass through the blood brain barrier and intestinal epithelial barrier and circulate freely in the blood stream without binding to human serum albumin. While the toxicity of one compound on the WS1 (skin fibroblast) cell line was 1790 μM, its toxicity on the SH-SY5Y (neuroblastoma) cell line was 950 μM.

Exocyclic N-Acyliminium Ion (NAI) Cyclization: Access to Fully Substituted Oxazoles and Furocoumarins

A concise, one-pot route to oxazoles and furocoumarins has been reported. The key step in this transformation involves in situ generation of N-acyliminium ion (NAI) precursor under catalyst and solvent-free conditions and their further transformations promoted by superacid in the same pot. We have also presented the experimental evidence for the involvement of proto-solvated novel exocyclic N-acyliminium ion. Further, the UV-visible and fluorescence studies revealed that few of the compounds reported here exhibited emission of blue light upon irradiation in EtOH in the region of 404-422 nm.

Oxidative C-C Bond Cleavage for the Synthesis of Aryl Carboxylic Acids from Aryl Alkyl Ketones

A metal-free and one-pot two-step synthesis of aryl carboxylic acids from aryl alkyl ketones has been achieved. The reactions were performed with iodine as the catalyst, DMSO and TBHP as the oxidants. Under the optimal reaction conditions, a number of aryl alkyl ketones could be converted into their corresponding aryl carboxylic acids in good to excellent yields (up to 94%).